Introduction
There is ample evidence to suggest that the primary mechanism by which organophosphorus toxins (OPs) used as insecticides or in chemical warfare (nerve agents) induce prolonged, severe seizures (status epilepticus; SE) involves hyperstimulation of muscarinic acetylcholine receptors (mAChRs). Thus, phosphorylation of acetylcholinesterase by these toxins, inactivates the enzyme (Sirin et al., 2012) , resulting in accumulation of acetylcholine at cholinergic synapses. Although both nicotinic acetylcholine receptors and mAChRs can be expected to be activated by the elevated acetylcholine, it is primarily the activation of mAChRs that elicits the generation of seizures. Evidence for that has been provided by studies showing that mAChR antagonists prevent the induction of seizures if administered before OP exposure (Ashani and Catravas, 1981; Capacio and Shih, 1991; McDonough et al., JPET 236125 5 (2003) have found that pilocarpine, a muscarinic agonist, induces SE in wild-type mice, but not in mice lacking the M 1 receptor, suggesting a key role for M 1 receptors in the induction of SE by pilocarpine. In addition, a highly selective M 1 receptor antagonist was developed recently, VU0255035 (Weaver et al., 2009) , and was tested against seizures induced by pilocarpine; mice pre-treated with VU0255035 did not develop SE, at least for 40 min after injection of pilocarpine (Sheffler et al., 2009) . Because pilocarpine and OPs share the primary mechanism of seizure induction (muscarinic receptor hyperstimulation), it has been suggested that findings in the pilocarpine model of SE may also apply to OP-induced SE (Tang et al., 2011; Tetz et al., 2006) .
Whether or not M 1 receptor activation, which is necessary for induction of seizures by pilocarpine, is also necessary for induction of seizures by OPs was recently tested in wild-type and M 1 -knockout mice (Kow et al., 2015) exposed to paraoxon (O,O-diethyl O-p-nitrophenyl phosphate), which is the active metabolite of the insecticide parathion (Garcia et al., 2003) . No difference was found in paraoxon-induced seizure severity between the wild-type and the M 1 -knockout mice, leading to the conclusion that in contrast to the significant role that the M 1 receptor plays in pilocarpine-induced seizures, these receptors are not involved in the generation of seizures by paraoxon exposure (Kow et al., 2015) . JPET 236125 paraoxon (paraoxon-ethyl; Sigma-Aldrich). The concentration of VU0255035 that we used is within the range that has no significant effect on cognitive functions (Sheffler et al., 2009) . For the soman experiments, animals were subcutaneously injected with 1.8 × LD 50 soman (198 μ g/kg, diluted in cold physiological saline). For the paraoxon experiments, animals were subcutaneously injected with 4 mg/kg paraoxon; paraoxon solutions were prepared fresh by adding 10 ml stock solution (1.274 g/mL) to 3 ml of ice cold PBS in a glass vial and mixing thoroughly. Soman was used because of its high toxicity and the difficulty in counteracting soman-induced seizures, which implies that if a drug is effective in suppressing seizures induced by soman, it is likely to be effective also against other nerve agents. Paraoxon was used because it is highly potent, has similar effects to those of soman, and there is extensive literature on its use as a model of OP poisoning, including its use as a surrogate for chemical warfare nerve agents. The peripheral toxic cholinergic effects of soman and paraoxon were controlled by intramuscular injection of either 2 mg/kg atropine methylnitrate, or 2 mg/kg atropine sulfate along with 25 mg/kg pralidoxime (2-PAM; all 3 drugs from Sigma-Aldrich), administered within 1 min after injection of the OP. Seizures were monitored behaviorally in a blind fashion by two expert observers, and their severity was scored for 1 h, using a modified version of the Racine scale (Racine, 1972), as we have described previously (Figueiredo et al., 2011) Islam, 2012; Apland et al., 2014; Deshpante et al., 2014; Rossetti et al., 2012) .
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Electrophysiology
Male rats, 25 to 30 days-old, were anesthetized with isoflurane prior to decapitation for preparation of brain slices. Coronal slices (400 μ m thick) containing the amygdala were cut as described previously (Aroniadou-Anderjaska et al., 2012) . Recording solution (artificial cerebrospinal fluid, ACSF) consisted of the following (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 21 NaHCO 3 , 2 CaCl 2 , 1 MgCl 2 , and 11 D-glucose. The ACSF was saturated with 95% O 2 / 5% CO 2 to achieve a pH near 7.4, and the osmolarity was adjusted to 325 mOsm with Dglucose. The slice chamber (0.7 ml capacity) had continuously flowing ACSF (~8 ml/min) at a temperature of 31-32 °C. Tight-seal (>1 GΩ), whole-cell recordings from principal neurons in the BLA were performed as described previously (Pidoplichko et al., 2014) . Neurons were visualized under infrared light using Nomarski optics of an upright microscope (Zeiss Axioskop 2, Thronwood, NY) through a 40x water immersion objective, equipped with a CCD-100 camera 
Statistical Analysis
Seizure score differences between the OP-exposed and the vehicle groups were tested for statistical significance using independent-samples Student's t-test. In vitro electrophysiological results were analyzed using paired Student's t-tests. Differences were considered statistically significant when P < 0.05. Data are presented as Means ± Standard Error of the Mean. Sample size "n" refers to the number of animals for the in vivo experiments and the number of recorded neurons for the whole-cell experiments.
Results
Effects of VU0255035 pretreatment on seizure severity after exposure to soman Eight rats were randomly divided into two groups: a group that was injected with VU0255035 (25 mg/kg, n = 4) and a group injected with the vehicle (DMSO; 1 ml/kg, n = 4), at 15 min before exposure to soman (198 μ g/kg). All rats developed seizures, and there was no statistically significant difference in seizure scores between the two groups at 5 min (0.75 ± 0.75 for the vehicle group and 2.5 ± 0.5 for the VU0255035 group; p = 0.1) or 10 min (3 ± 0 for the vehicle group and 2.75 ± 0.25 for the VU0255035 group; p = 0.3) after injection of soman.
However, for the next 35 min, Racine scale scores for the VU2055035 group were significantly lower compared to the vehicle group (Fig. 1A) . At 15 min post-soman injection, the seizure score for the VU0255035 group, p = 0.052; at 55 min, 5 ± 1 for the vehicle group and 3 ± 0.41 for the VU0255035 group, p = 0.09; and at 60 min, 5 ± 1 for the vehicle group and 3.25 ± 0.25 for the VU0255035 group, p = 0.10). These results are summarized in Table 1 .
Effects of VU0255035 pretreatment on seizure severity after exposure to paraoxon
Next, we examined if pretreatment with VU0255035 also decreases seizure severity after exposure to paraoxon. Because behavioral seizure score did not differ between the VU0255035 group and the vehicle group during the first 10 min after soman exposure (Fig. 1A) , with VU0255035 administered 15 min before soman injection, this time we administered VU0255035 30 min before paraoxon exposure, considering that perhaps 15 min were not sufficient for VU0255035 to take full effect. Eleven rats were randomly divided into two groups: a group that was injected with 25 mg/kg VU0255035 (n = 6) and a group injected with the vehicle (DMSO; 1 JPET 236125 1 1 ml/kg, n = 5), at 30 min before exposure to paraoxon (4 mg/kg). All rats developed seizures.
Again, the Racine score did not differ significantly between the two groups during the first 10 min after paraoxon injection (at 5 min, 3.33 ± 0.24 for the vehicle group and 3.4 ± 0.21 for the VU0255035 group, p = 0.8; at 10 min, 4.33 ± 0.8 for the vehicle group and 3.8 ± 0.33 for the VU0255035 group, p = 0.5). However, for the next 30 min, Racine scale scores for the VU2055035 group were significantly lower compared to the vehicle group (Fig. 1B) . At 15 min post-paraoxon injection, the seizure score was 4 ± 0.37 for the vehicle group and 2. barrage of large-amplitude sIPSCs with a duration of 1.1 ± 0.1 min (n = 21), which was followed by a lasting enhancement of preferentially sEPSCs ( Fig. 2A) . Paraoxon took effect (appearance of the barrage of sIPSCs) within 2 to 8 min after application, depending on the concentration (the lower concentration of paraoxon was slower to take effect). To quantify the relative increase of excitatory synaptic activity by paraoxon, we calculated the charge transferred by the excitatory and the inhibitory currents, during a 20 s time-window, in control conditions, and then again after paraoxon had taken effect; the charge transferred, in picoCoulombs, was calculated as the area delimited by the excitatory or inhibitory current and the baseline. The ratio of the charge transferred by sEPSCs to the charge transferred by sIPSCs was increased significantly in the presence of paraoxon. When 0.1 μ M paraoxon was applied, the sEPSC/sIPSC ratio was increased from 0.6 ± 0.1 in control conditions to 1.4 ± 0.3 at 17 min after paraoxon application (P < 0.05, n = 7). When 1 μ M paraoxon was applied, the sEPSC/sIPSC ratio was increased from 0.6 ± 0.1 in control conditions to 0.9 ± 0.1 at 9 min after paraoxon application (P < 0.05, n = 4).
Finally, when 10 μ M paraoxon was applied, the ratio of sEPSC/sIPSC charge transfer was increased from 0.8 ± 0.1 in control conditions to 1.1 ± 0.1 at 6 min after paraoxon application (P < 0.01, n = 10; Fig. 2B ). Paraoxon, in the presence of atropine, had no significant effect on sIPSCs or sEPSCs (Fig. 3A, top traces). The total charge transferred by sIPSCs or sEPSCs during a 20 s time-window, 10 min after paraoxon application, was expressed as a percentage of the total charge transferred, during 20 s, in control conditions (in the presence of atropine). When 1 μ M atropine was present in the slice medium, the charge transferred by sIPSCs after 10 min in paraoxon was 72 ± 25% of the control (n = 7, P = 0.203), while the charge transferred by sEPSCs was 79 ± 23% of the control (n = 7, P = 0.055; Fig 3B, left bar graph) . Next, we performed similar experiments in the presence of VU0255035, to determine whether the M 1 receptor was involved in mediating the effects of paraoxon. In 10 μ M VU0255035, paraoxon had no significant effect on sIPSCs or sEPSCs (Fig. 3A, lower traces) ; the charge transferred by sIPSCs after 10 min in paraoxon was 75 ± 17% of the VU0255035-containing control (n = 7, P = 0.156), while the charge transferred by sEPSCs was 81 ± 16% of the VU0255035-containing control (n = 7, P = 0.389; Fig. 3B , middle bar graph). These results are in contrast to the effects of 10 μ M paraoxon in the absence of muscarinic receptor antagonists ( Fig. 2A, third row of traces) ; under these conditions, the charge transferred by sIPSCs was increased by paraoxon to 275 ± 57% of the control (n = 10, P = 0.0001), and the charge transferred by sEPSCs was increased by paraoxon to 435 ± 80% of the control (n = 10, P = 0.00002; Fig. 3B, right bar graph) . The difference between the increase in sIPSCs and the increase in sEPSCs was statistically significant (P < 0.001).
Effects of paraoxon on the Ih current
This article has not been copyedited and formatted. The final version may differ from this version. there was no effect on the Ih (Fig. 4D) . These results suggest that the enhancement of Ih by paraoxon was mediated by M 1 receptor activation.
Discussion
The present study demonstrated that pretreatment with the selective M 1 receptor antagonist VU0255035 significantly suppresses behavioral seizures induced by either soman or paraoxon, for at least 40 min after exposure, preventing the development of SE during this time period. The in vitro experiments aiming to uncover some of the mechanisms involved in seizure generation by paraoxon and the involvement of M 1 receptors, showed that paraoxon enhances both inhibitory and excitatory spontaneous activity recorded from BLA principal cells, with a lasting greater increase in sEPSCs, such that the ratio of the charge transferred by sEPSCs over that of sIPSCs is increased; these effects of paraoxon are blocked in the presence of VU0255035.
This article has not been copyedited and formatted. The final version may differ from this version. The data in the present study make it evident that during the first 10 min after OP injection, low intensity seizures were initiated despite the VU0255035 pretreatment. Behavioral seizures stage 2 to 3 and slightly higher which correspond to epileptic discharges on EEG ( (2013) found that in the small proportion of rats who do not develop SE when exposed to high doses of soman, the activity of acetylcholinesterase is reduced in the hippocampus and the piriform cortex to a similar extent as in the rats who develop SE, but to a significantly lesser extent in the BLA; this suggests a critical role of acetylcholinesterase reduction in the BLA for SE to be induced. The importance of the amygdala in nerve agent-induced seizure generation is also highlighted by the findings that the amygdala displays the earliest increase in extracellular glutamate after exposure to soman (Lallement et al., 1991) , and generates ictal-like discharges after in vitro application of soman (Apland et al., 2009) . It is to be expected, therefore, that when the BLA is exposed to an OP, neuronal excitability will increase, which will be reflected in an increase of spontaneous glutamatergic activity. Indeed, in the present study, paraoxon increased sEPSCs in the BLA significantly more than the increase of sIPSCs.
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The cellular location of these receptors where paraoxon acted remains to be determined.
Cholinergic synapses in the BLA are formed by the dense cholinergic afferents arising from the basal forebrain (Ben-Ari et al., 1977; Carlsen and Heimer, 1986; Muller et al., 2011; Nagai et al., 1982) , but also by an intrinsic population of small cholinergic neurons (Carlsen and Heimer, 1986) . Cholinergic nerve terminals synapse on both pyramidal cells and interneurons (Carlsen and Heimer, 1986; Muller et al., 2011; Nitecka and Frotscher, 1989) , but the majority of the cholinergic input is directed onto pyramidal neurons (Muller et al., 2011) . From the different types of mAChRs, both the M 1 and M 2 subtypes are present in the rat BLA (Cortes and Palacios, 1986; Mash and Potter, 1986; Mash et al., 1988; Spencer et al., 1986) , as well as the M 3 and/or M 4 receptors (Smith et al., 1991) , but the M 1 receptors predominate (Buckley et al., 1988) .
Immunocytochemistry along with electron microscopy have revealed that M 1 receptors in the rat BLA are located on somata, dendritic shafts, and, to a lesser extent, spines of pyramidal neurons, as well as on aspiny dendrites with morphological features typical of interneurons (Muller et al., 2013) . In addition, M 1 immunoreactivity has been found on presynaptic terminals, most of which formed asymmetrical synapses with dendritic spines, but some of which formed symmetrical synapses with neuronal somata and dendritic shafts (Muller et al., 2013 ). It appears, therefore, that M 1 receptors in the rat BLA are in a position to affect the activity of both glutamatergic and Administration of VU0255035 (25 mg/kg), 30 min before exposure to paraoxon (4 mg/kg), significantly reduced seizure severity scores from 15 min to 40 min after paraoxon injection (n = 6 in the VU0255035 group and n = 5 in the vehicle group; *p < 0.05, **p < 0.01, ***p < 0.001). antagonists (right bar graph; n = 10). The total charge transferred by sIPSCs or sEPSCs during a 20 s time-window, 10 min after paraoxon application, was expressed as a percentage of the total charge transferred, during 20 s, in control conditions. Only when there was no atropine or VU0255035 in the slice medium, the total charge transferred by sIPSCs and sEPSCs was increased by paraoxon, and the difference between the increase in sIPSCs and the increase in sEPSCs was statistically significant (***P < 0.001). 
